IN184589B
(th)
*
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
US7258869B1
(en)
*
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
AU2046101A
(en)
*
|
1999-11-22 |
2001-06-04 |
Universal Preservation Technologies, Inc. |
Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
|
US7456009B2
(en)
*
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
US20020041884A1
(en)
*
|
2000-03-07 |
2002-04-11 |
Evans Robert K. |
Adenovirus formulations
|
US7153472B1
(en)
|
2000-11-22 |
2006-12-26 |
Quadrant Drug Delivery Limited |
Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
|
ATE285756T1
(de)
*
|
2001-06-28 |
2005-01-15 |
Microchips Inc |
Verfahren zum hermetischen versiegeln von mikrochip-reservoir-vorrichtungen
|
WO2003048665A1
(en)
|
2001-12-03 |
2003-06-12 |
Massachusetts Institute Of Technology |
Microscale lyophilization and drying methods for the stabilization of molecules
|
NZ534377A
(en)
*
|
2002-03-13 |
2008-04-30 |
Collagenex Pharm Inc |
Water-based topical delivery system consisting of cholesterol, fatty acids water and a phospholipid/ceramide portion.
|
CN100594892C
(zh)
*
|
2002-08-16 |
2010-03-24 |
微芯片公司 |
使用电热消融的受控释放的装置和方法
|
WO2004022033A1
(en)
*
|
2002-09-04 |
2004-03-18 |
Microchips, Inc. |
Method and device for the controlled delivery of parathyroid hormone
|
AU2003269213B2
(en)
*
|
2002-09-27 |
2008-11-13 |
Powderject Research Limited |
Nucleic acid coated particles
|
EP1551499A1
(en)
|
2002-10-04 |
2005-07-13 |
Microchips, Inc. |
Medical device for neural stimulation and controlled drug delivery
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
AU2003299795A1
(en)
|
2002-12-20 |
2004-07-22 |
Xeris Pharmaceuticals, Inc. |
Intracutaneous injection
|
WO2004091495A2
(en)
*
|
2003-04-09 |
2004-10-28 |
University Of Utah Research Foundation |
Compositions and methods related to production of erythropoietin
|
ES2359243T3
(es)
*
|
2003-04-25 |
2011-05-19 |
Boston Scientific Scimed, Inc. |
Formulación de fármaco sólida y dispositivo para el almacenamiento y la administración controlada de la misma.
|
US7892205B2
(en)
|
2003-06-06 |
2011-02-22 |
Boston Scientific Scimed, Inc. |
Device and method for delivering micronized therapeutic agents in the body
|
WO2005041767A2
(en)
*
|
2003-11-03 |
2005-05-12 |
Microchips, Inc. |
Medical device for sensing glucose
|
CA2569375A1
(en)
*
|
2004-06-01 |
2006-08-17 |
Microchips, Inc. |
Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
|
WO2006015299A2
(en)
*
|
2004-07-30 |
2006-02-09 |
Microchips, Inc. |
Multi-reservoir device for transdermal drug delivery and sensing
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
WO2006026768A1
(en)
*
|
2004-09-01 |
2006-03-09 |
Microchips, Inc. |
Multi-cap reservoir devices for controlled release or exposure of reservoir contents
|
JP4999692B2
(ja)
|
2004-09-10 |
2012-08-15 |
ベクトン・ディキンソン・アンド・カンパニー |
再形成注入装置
|
AU2006208131A1
(en)
|
2005-01-25 |
2006-08-03 |
Microchips, Inc. |
Control of drug release by transient modification of local microenvironments
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US9301919B2
(en)
*
|
2005-12-22 |
2016-04-05 |
Oakwood Laboratories, Llc |
Sublimable sustained release delivery system and method of making same
|
AU2007266475B2
(en)
|
2006-05-30 |
2009-12-03 |
Intarcia Therapeutics, Inc. |
Two-piece, internal-channel osmotic delivery system flow modulator
|
AU2007284759B2
(en)
|
2006-08-09 |
2010-10-28 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies
|
SI2134353T1
(sl)
*
|
2007-03-30 |
2017-03-31 |
Xisle Pharma Ventures Trust |
Dvofazni sestavek lipidnih veziklov in postopek za zdravljenje cervikalne displazije z intravaginalnim dajanjem
|
CN105688191A
(zh)
|
2007-04-23 |
2016-06-22 |
精达制药公司 |
促胰岛素释放肽的混悬制剂及其应用
|
CA2691531C
(en)
|
2007-06-22 |
2016-11-01 |
Board Of Regents,The University Of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
DK2240155T3
(da)
*
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
CA2743789C
(en)
|
2008-11-16 |
2017-10-31 |
Board Of Regents, The Univesity Of Texas System |
Low viscosity highly concentrated suspensions
|
US9283184B2
(en)
*
|
2008-11-24 |
2016-03-15 |
Massachusetts Institute Of Technology |
Methods and compositions for localized agent delivery
|
MX352878B
(es)
|
2009-09-28 |
2017-12-13 |
Intarcia Therapeutics Inc |
Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
EP2544721B1
(en)
*
|
2010-03-09 |
2017-12-06 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations
|
US20110223208A1
(en)
*
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
WO2011113855A2
(en)
|
2010-03-17 |
2011-09-22 |
Novaliq Gmbh |
Pharmaceutical composition for treatment of increased intraocular pressure
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
EP2444063A1
(en)
|
2010-10-20 |
2012-04-25 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the delivery of active ingredients
|
EP2462921A1
(en)
|
2010-11-11 |
2012-06-13 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the treatment of a posterior eye disease
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
SG193389A1
(en)
|
2011-03-10 |
2013-10-30 |
Xeris Pharmaceuticals Inc |
Stable formulations for parenteral injection of peptide drugs
|
ES2617968T3
(es)
|
2011-05-25 |
2017-06-20 |
Novaliq Gmbh |
Composición farmacéutica para la administración a uñas
|
WO2012160179A2
(en)
|
2011-05-25 |
2012-11-29 |
Novaliq Gmbh |
Topical pharmaceutical composition based on semifluorinated alkanes
|
EP2773331B1
(en)
|
2011-10-31 |
2016-02-10 |
Xeris Pharmaceuticals, Inc. |
Formulations for the treatment of diabetes
|
ES2625538T3
(es)
|
2012-01-23 |
2017-07-19 |
Novaliq Gmbh |
Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
|
US9125805B2
(en)
|
2012-06-27 |
2015-09-08 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of small molecule drugs
|
KR102171897B1
(ko)
|
2012-09-12 |
2020-11-02 |
노바리크 게엠베하 |
부분불소화 알칸 조성물
|
CN113679697A
(zh)
|
2012-09-12 |
2021-11-23 |
诺瓦利克有限责任公司 |
包含半氟化烷烃的混合物的组合物
|
US9505737B2
(en)
|
2013-01-11 |
2016-11-29 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
ES2927844T3
(es)
|
2013-01-11 |
2022-11-11 |
Corsair Pharma Inc |
Profármacos de treprostinil
|
US9018162B2
(en)
|
2013-02-06 |
2015-04-28 |
Xeris Pharmaceuticals, Inc. |
Methods for rapidly treating severe hypoglycemia
|
SG10201707600XA
(en)
*
|
2013-03-15 |
2017-11-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
EP3024484B1
(en)
|
2013-07-23 |
2018-06-20 |
Novaliq GmbH |
Stabilized antibody compositions
|
US8986732B2
(en)
|
2013-08-12 |
2015-03-24 |
Helix Biopharma Corporation |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
US10159646B2
(en)
|
2013-08-12 |
2018-12-25 |
Altum-Avro Pharma Partnership |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
ES2959451T3
(es)
|
2013-09-11 |
2024-02-26 |
Eagle Biologics Inc |
Formulaciones proteicas líquidas que contienen organofosfatos
|
ES2904276T3
(es)
|
2013-09-27 |
2022-04-04 |
Massachusetts Inst Technology |
Nanoestructuras de proteínas biológicamente activas sin vehículo
|
JP7058940B2
(ja)
*
|
2014-03-24 |
2022-04-25 |
バイオベラティブ セラピューティクス インコーポレイテッド |
凍結乾燥第ix因子製剤
|
WO2016010538A1
(en)
|
2014-07-16 |
2016-01-21 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
US11129940B2
(en)
|
2014-08-06 |
2021-09-28 |
Xeris Pharmaceuticals, Inc. |
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
KR102497368B1
(ko)
|
2014-10-01 |
2023-02-10 |
이글 바이올로직스 인코포레이티드 |
점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
|
CN113598842A
(zh)
|
2015-06-03 |
2021-11-05 |
因塔西亚制药公司 |
植入物放置和移除系统
|
US9649364B2
(en)
|
2015-09-25 |
2017-05-16 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic formulations in aprotic polar solvents
|
US9643911B2
(en)
|
2015-06-17 |
2017-05-09 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
US9394227B1
(en)
|
2015-06-17 |
2016-07-19 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
EP3334417A4
(en)
|
2015-08-12 |
2019-07-17 |
Massachusetts Institute of Technology |
CELL SURFACE COUPLING OF NANOPARTICLES
|
US11590205B2
(en)
|
2015-09-25 |
2023-02-28 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
|
DK3722274T3
(da)
|
2015-09-30 |
2023-09-11 |
Novaliq Gmbh |
2-perfluorbutylpentan til oftalmisk indgivelse
|
CN111743882A
(zh)
|
2015-09-30 |
2020-10-09 |
诺瓦利克有限责任公司 |
半氟化化合物和其组合物
|
MX2018014016A
(es)
|
2016-05-16 |
2019-08-01 |
Intarcia Therapeutics Inc |
Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
AU2017283480A1
(en)
|
2016-06-13 |
2019-01-24 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
WO2017220625A1
(en)
|
2016-06-23 |
2017-12-28 |
Novaliq Gmbh |
Topical administration method
|
AU2017329772B2
(en)
|
2016-09-22 |
2023-02-02 |
Novaliq Gmbh |
Pharmaceutical compositions for use in the therapy of blepharitis
|
WO2018055101A1
(en)
|
2016-09-23 |
2018-03-29 |
Novaliq Gmbh |
Ophthalmic compositions comprising ciclosporin
|
EP3565580B1
(en)
|
2017-01-03 |
2024-03-06 |
i2o Therapeutics, Inc. |
Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
|
KR102351816B1
(ko)
|
2017-04-21 |
2022-01-17 |
노바리크 게엠베하 |
요오드 조성물
|
EP3621601A1
(en)
|
2017-05-12 |
2020-03-18 |
Novaliq GmbH |
Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
|
US10646569B2
(en)
|
2017-05-16 |
2020-05-12 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
CN117085022A
(zh)
|
2017-06-02 |
2023-11-21 |
Xeris药物公司 |
抗沉淀的小分子药物制剂
|
EP3678701A4
(en)
|
2017-09-05 |
2021-12-01 |
Torque Therapeutics, Inc. |
THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF
|
CN111372566A
(zh)
|
2017-09-27 |
2020-07-03 |
诺瓦利克有限责任公司 |
用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
|
US11896559B2
(en)
|
2017-10-04 |
2024-02-13 |
Novaliq Gmbh |
Opthalmic compositions comprising F6H8
|
US11576893B2
(en)
|
2018-03-02 |
2023-02-14 |
Novaliq Gmbh |
Pharmaceutical compositions comprising nebivolol
|
WO2019217637A1
(en)
*
|
2018-05-09 |
2019-11-14 |
Biomatrica, Inc. |
Stabilization of proteins in biological samples
|
CA3112031A1
(en)
|
2018-10-12 |
2020-04-16 |
Novaliq Gmbh |
Ophthalmic composition for treatment of dry eye disease
|
JP2022519690A
(ja)
|
2019-02-05 |
2022-03-24 |
リンディー バイオサイエンシーズ,インク. |
単離された細胞培養成分、及びそれを液状の細胞培養培地から単離する方法
|
CN115397480A
(zh)
*
|
2019-12-06 |
2022-11-25 |
广州倍绣生物技术有限公司 |
可流动纤维蛋白原凝血酶糊剂
|
WO2023044455A2
(en)
*
|
2021-09-16 |
2023-03-23 |
Team Medical Llc |
Rna stabilization
|